A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Adding an ICI to neoadjuvant chemotherapy can improve pCR rates and may improve OS in patients with MIBC, research suggests.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Trials are testing Imfinzi (durvalumab), AstraZeneca’s anti PD-L1 antibody, combined with Celgene’s immunomodulatory and chemotherapy agents in blood cancers such as multiple myeloma ...

The EMA's human medicines committee (CHMP) has backed approval of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA4 inhibitor Imjudo (tremelimumab) as a first-line treatment for advanced or ...

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...